Therapeutic Drug Monitoring of Voriconazole After Intravenous Administration in Infants and Children With Primary Immunodeficiency

被引：17

作者：

Gerin, Magdalena ^{[2
,3
,4
]}

Mahlaoui, Nizar ^{[2
,4
,5
]}

Elie, Caroline ^{[2
,6
]}

Lanternier, Fanny ^{[2
,3
,4
]}

Bougnoux, Marie-Elisabeth ^{[2
,4
,7
]}

Blanche, Stephane ^{[2
,4
,5
]}

Lortholary, Olivier ^{[2
,3
,4
,8
,9
]}

Jullien, Vincent ^{[1
,2
]}

机构：

[1] Hop St Vincent de Paul, Serv Pharmacol Clin, INSERM, U663, F-75014 Paris, France

[2] Univ Paris 05, AP HP, Paris, France

[3] Ctr Infect Necker Pasteur, Serv Malad Infect & Trop, Paris, France

[4] Hop Necker Enfants Malad, Paris, France

[5] Unite Immunol Hematol Pediat, Paris, France

[6] Serv Biostat, Paris, France

[7] Microbiol Serv, Paris, France

[8] Ctr Natl Reference Mycol & Antifong, Unite Mycol Mol, Inst Pasteur, Paris, France

[9] CNRS, URA 3012, Paris, France

来源：

THERAPEUTIC DRUG MONITORING | 2011年 / 33卷 / 04期

关键词：

therapeutic drug monitoring; voriconazole; primary immunodeficiency; children; infants; intravenous administration; immunodeficiency; PLASMA; POPULATION;

D O I：

10.1097/FTD.0b013e3182241b2b

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

Objective: A voriconazole trough concentration (C(trough)) <1 mg/L is associated with a higher risk of treatment failure. The aim of this work was to describe the probability of not achieving this target concentration in infants and children receiving intravenous voriconazole. Methods: Voriconazole trough concentrations obtained during routine therapeutic drug monitoring over a 5-year period were collected retrospectively from infants and children receiving intravenous voriconazole for presumed or proven invasive fungal infections. Results: Sixty-two trough concentrations were obtained from 6 infants and 10 children. The risk of a C(trough) <1 mg/L was 77% and 47%, respectively. Daily doses between 20 and 32 mg/kg were necessary in some patients to achieve a C(trough) >1 mg/L, compared with the currently recommended 14-mg/kg regimen. Conclusions: Routine therapeutic drug monitoring is potentially helpful in infants and children receiving voriconazole, even intravenously.

引用

页码：464 / 466

页数：3

共 10 条

[1] IMPACT OF THERAPEUTIC DRUG MONITORING OF VORICONAZOLE IN A PEDIATRIC POPULATION [J].

Brueggemann, Roger J. M. ;

van der Linden, Jan W. M. ;

Verweij, Paul E. ;

Burger, David M. ;

Warris, Adilia .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2011, 30 (06) :533-534

[2] Simultaneous quantification of voriconazole and posaconazole in human plasma by high-performance liquid chromatography with ultra-violet detection [J].

Chhun, Stephanie ;

Rey, Elisabeth ;

Tran, Agnes ;

Lortholary, Olivier ;

Pons, Gerard ;

Jullien, Vincent .

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2007, 852 (1-2) :223-228

[3] Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group [J].

De Pauw, Ben ;

Walsh, Thomas J. ;

Donnelly, J. Peter ;

Stevens, David A. ;

Edwards, John E. ;

Calandra, Thierry ;

Pappas, Peter G. ;

Maertens, Johan ;

Lortholary, Olivier ;

Kauffman, Carol A. ;

Denning, David W. ;

Patterson, Thomas F. ;

Maschmeyer, Georg ;

Bille, Jacques ;

Dismukes, William E. ;

Herbrecht, Raoul ;

Hope, William W. ;

Kibbler, Christopher C. ;

Kullberg, Bart Jan ;

Marr, Kieren A. ;

Munoz, Patricia ;

Odds, Frank C. ;

Perfect, John R. ;

Restrepo, Angela ;

Ruhnke, Markus ;

Segal, Brahm H. ;

Sobel, Jack D. ;

Sorrell, Tania C. ;

Viscoli, Claudio ;

Wingard, John R. ;

Zaoutis, Theoklis ;

Bennett, John E. .

CLINICAL INFECTIOUS DISEASES, 2008, 46 (12) :1813-1821

[4] Population Pharmacokinetic Analysis of Voriconazole Plasma Concentration Data from Pediatric Studies [J].

Karlsson, Mats O. ;

Lutsar, Irja ;

Milligan, Peter A. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (03) :935-944

[5] Voriconazole Pharmacokinetics and Pharmacodynamics in Children [J].

Neely, Michael ;

Rushing, Teresa ;

Kovacs, Andrea ;

Jelliffe, Roger ;

Hoffman, Jill .

CLINICAL INFECTIOUS DISEASES, 2010, 50 (01) :27-36

[6] Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes [J].

Pascual, Andres ;

Calandra, Thierry ;

Bolay, Saskia ;

Buclin, Thierry ;

Bille, Jacques ;

Marchetti, Oscar .

CLINICAL INFECTIOUS DISEASES, 2008, 46 (02) :201-211

[7] Differences in Voriconazole Trough Plasma Concentrations per Oral Dosages Between Children Younger and Older Than 3 Years of Age [J].

Shima, Haruko ;

Miharu, Masashi ;

Osumi, Tomoo ;

Takahashi, Takao ;

Shimada, Hiroyuki .

PEDIATRIC BLOOD & CANCER, 2010, 54 (07) :1050-1052

[8] Voriconazole therapeutic drug monitoring [J].

Smith, J ;

Safdar, N ;

Knasinski, V ;

Simmons, W ;

Bhavnani, SM ;

Ambrose, PG ;

Andes, D .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (04) :1570-1572

[9] Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities [J].

Tan, K ;

Brayshaw, N ;

Tomaszweski, K ;

Troke, P ;

Wood, N .

JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (02) :235-243

[10] Effect of omeprazole on the steady-state pharmacokinetics of voriconazole [J].

Wood, N ;

Tan, K ;

Purkins, L ;

Layton, G ;

Hamlin, J ;

Kleinermans, D ;

Nichols, D .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 :56-61

← 1 →